Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan

Our challenges for the future

Akira Hirasawa, Kenta Masuda, Tomoko Akahane, Tomohiko Tsuruta, Kouji Banno, Kazuya Makita, Nobuyuki Susumu, Hiromitsu Jinno, Yuko Kitagawa, Kokichi Sugano, Kenjiro Kosaki, Daisuke Aoki

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Risk-reducing salpingo-oophorectomy is currently regarded as the most certain primary method for preventing ovarian cancer among BRCA1/2 mutation carriers with hereditary breast and ovarian cancer syndrome. However, risk-reducing salpingo-oophorectomy has rarely been performed in Japan. Methods: We developed the first system in Japan for performing risk-reducing salpingooophorectomy for BRCA1/2 mutation carriers at our university hospital in 2008. Results: The indication for risk-reducing salpingo-oophorectomy for patients with hereditary breast/ovarian cancer syndrome is currently limited in Japan. This situation may be because of the limited number of genetic counseling units, the limited number of facilities that can perform BRCA1/2 genetic testing and the fact that prophylactic surgery is not covered by health insurance in Japan. Conclusions: Recent treatment guidelines for breast cancer in Japan recommended riskreducing salpingo-oophorectomy for BRCA1/2 mutation carriers. Risk-reducing salpingooophorectomy should be performed in the framework of the standard therapeutic modality for BRCA1/2 mutation carriers in the near future.

Original languageEnglish
Pages (from-to)515-519
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume43
Issue number5
DOIs
Publication statusPublished - May 1 2013
Externally publishedYes

Fingerprint

Hereditary Breast and Ovarian Cancer Syndrome
Ovariectomy
Japan
Mutation
Genetic Counseling
Genetic Testing
Health Insurance
Ovarian Neoplasms
Guidelines
Breast Neoplasms
Therapeutics

Keywords

  • BRCA1
  • BRCA2
  • Hereditary breast and ovarian cancer syndrome
  • Mutation carrier
  • Risk-reducing salpingo-oophorectomy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan : Our challenges for the future. / Hirasawa, Akira; Masuda, Kenta; Akahane, Tomoko; Tsuruta, Tomohiko; Banno, Kouji; Makita, Kazuya; Susumu, Nobuyuki; Jinno, Hiromitsu; Kitagawa, Yuko; Sugano, Kokichi; Kosaki, Kenjiro; Aoki, Daisuke.

In: Japanese Journal of Clinical Oncology, Vol. 43, No. 5, 01.05.2013, p. 515-519.

Research output: Contribution to journalArticle

Hirasawa, Akira ; Masuda, Kenta ; Akahane, Tomoko ; Tsuruta, Tomohiko ; Banno, Kouji ; Makita, Kazuya ; Susumu, Nobuyuki ; Jinno, Hiromitsu ; Kitagawa, Yuko ; Sugano, Kokichi ; Kosaki, Kenjiro ; Aoki, Daisuke. / Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan : Our challenges for the future. In: Japanese Journal of Clinical Oncology. 2013 ; Vol. 43, No. 5. pp. 515-519.
@article{2dd6168a5bbc479381a96e54af59e06c,
title = "Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: Our challenges for the future",
abstract = "Background: Risk-reducing salpingo-oophorectomy is currently regarded as the most certain primary method for preventing ovarian cancer among BRCA1/2 mutation carriers with hereditary breast and ovarian cancer syndrome. However, risk-reducing salpingo-oophorectomy has rarely been performed in Japan. Methods: We developed the first system in Japan for performing risk-reducing salpingooophorectomy for BRCA1/2 mutation carriers at our university hospital in 2008. Results: The indication for risk-reducing salpingo-oophorectomy for patients with hereditary breast/ovarian cancer syndrome is currently limited in Japan. This situation may be because of the limited number of genetic counseling units, the limited number of facilities that can perform BRCA1/2 genetic testing and the fact that prophylactic surgery is not covered by health insurance in Japan. Conclusions: Recent treatment guidelines for breast cancer in Japan recommended riskreducing salpingo-oophorectomy for BRCA1/2 mutation carriers. Risk-reducing salpingooophorectomy should be performed in the framework of the standard therapeutic modality for BRCA1/2 mutation carriers in the near future.",
keywords = "BRCA1, BRCA2, Hereditary breast and ovarian cancer syndrome, Mutation carrier, Risk-reducing salpingo-oophorectomy",
author = "Akira Hirasawa and Kenta Masuda and Tomoko Akahane and Tomohiko Tsuruta and Kouji Banno and Kazuya Makita and Nobuyuki Susumu and Hiromitsu Jinno and Yuko Kitagawa and Kokichi Sugano and Kenjiro Kosaki and Daisuke Aoki",
year = "2013",
month = "5",
day = "1",
doi = "10.1093/jjco/hyt036",
language = "English",
volume = "43",
pages = "515--519",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan

T2 - Our challenges for the future

AU - Hirasawa, Akira

AU - Masuda, Kenta

AU - Akahane, Tomoko

AU - Tsuruta, Tomohiko

AU - Banno, Kouji

AU - Makita, Kazuya

AU - Susumu, Nobuyuki

AU - Jinno, Hiromitsu

AU - Kitagawa, Yuko

AU - Sugano, Kokichi

AU - Kosaki, Kenjiro

AU - Aoki, Daisuke

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Background: Risk-reducing salpingo-oophorectomy is currently regarded as the most certain primary method for preventing ovarian cancer among BRCA1/2 mutation carriers with hereditary breast and ovarian cancer syndrome. However, risk-reducing salpingo-oophorectomy has rarely been performed in Japan. Methods: We developed the first system in Japan for performing risk-reducing salpingooophorectomy for BRCA1/2 mutation carriers at our university hospital in 2008. Results: The indication for risk-reducing salpingo-oophorectomy for patients with hereditary breast/ovarian cancer syndrome is currently limited in Japan. This situation may be because of the limited number of genetic counseling units, the limited number of facilities that can perform BRCA1/2 genetic testing and the fact that prophylactic surgery is not covered by health insurance in Japan. Conclusions: Recent treatment guidelines for breast cancer in Japan recommended riskreducing salpingo-oophorectomy for BRCA1/2 mutation carriers. Risk-reducing salpingooophorectomy should be performed in the framework of the standard therapeutic modality for BRCA1/2 mutation carriers in the near future.

AB - Background: Risk-reducing salpingo-oophorectomy is currently regarded as the most certain primary method for preventing ovarian cancer among BRCA1/2 mutation carriers with hereditary breast and ovarian cancer syndrome. However, risk-reducing salpingo-oophorectomy has rarely been performed in Japan. Methods: We developed the first system in Japan for performing risk-reducing salpingooophorectomy for BRCA1/2 mutation carriers at our university hospital in 2008. Results: The indication for risk-reducing salpingo-oophorectomy for patients with hereditary breast/ovarian cancer syndrome is currently limited in Japan. This situation may be because of the limited number of genetic counseling units, the limited number of facilities that can perform BRCA1/2 genetic testing and the fact that prophylactic surgery is not covered by health insurance in Japan. Conclusions: Recent treatment guidelines for breast cancer in Japan recommended riskreducing salpingo-oophorectomy for BRCA1/2 mutation carriers. Risk-reducing salpingooophorectomy should be performed in the framework of the standard therapeutic modality for BRCA1/2 mutation carriers in the near future.

KW - BRCA1

KW - BRCA2

KW - Hereditary breast and ovarian cancer syndrome

KW - Mutation carrier

KW - Risk-reducing salpingo-oophorectomy

UR - http://www.scopus.com/inward/record.url?scp=84877355104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877355104&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt036

DO - 10.1093/jjco/hyt036

M3 - Article

VL - 43

SP - 515

EP - 519

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 5

ER -